Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.84 |
| ▸ | TP53 | P04637 | 7/20 | 0.84 |
| ▸ | TSHR | P16473 | 7/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | F8 | P00451 | 1/20 | 0.75 |
| ▸ | F5 | P12259 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629030 | 0.99 | SMN1; SMN2 (0.82) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749545 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749572 | 0.84 | MAPK1 (0.79) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749647 | 0.82 | LMNA (0.83) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749611 | 0.81 | POLB (0.78) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL2495262 | 0.81 | LMNA (0.91) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749592 | 0.81 | LMNA (0.68) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL2496035 | 0.80 | LMNA (0.89) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749631 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2TP53TSHRALOX15LMNA | |
| SCHEMBL17749610 | 0.78 | LMNA (0.80) | SMN1; SMN2TP53TSHRALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | SMN1; SMN2 73/4885TP53 1897/4885TSHR 4456/4885 |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | SMN1; SMN2 73/4885TP53 1897/4885TSHR 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.